Back to search results

Exercise Training After Breast Cancer Chemotherapy

This study is looking at how different types of exercise can help breast cancer survivors improve their heart health after chemotherapy. Chemotherapy is very effective, but it can increase the risk of heart problems. Researchers want to see if high-intensity interval training (HIIT) or moderate-intensity continuous training (MICT) can help reduce these risks. You might be able to join if you are a woman between 18 and 85 years old, have had stages I-III breast cancer, and completed chemotherapy (anthracycline, alkylating agent, and/or taxane) between 6 and 18 months ago. The study will measure changes in your blood vessel function and heart function to see how well the exercises work and how long the benefits last. The study is currently recruiting participants.

Study design
This study will randomly assign 158 participants to one of three groups: high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or usual care.
What's involved
Participants will engage in a 12-week intervention period of exercise or usual care, followed by a 12-week observation period. Heart and blood vessel function will be measured at the start, after 12 weeks, and after 24 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be observed for 12 weeks after the initial 12-week intervention period to assess the long-term effects of the exercises.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05913713

HIIT Following Breast Cancer Chemotherapy

Active, Not Recruiting
NAAges 18–85InterventionalPrevention
University of Florida
~158 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:12-week Intervention Period12-week Observation Period

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in brachial FMD
Measured over Baseline, Following a 12-week intervention period, Following a 12-week observation period
+5 more outcomes measured

Conditions

Breast Cancer

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Demetra Christou, PhD · PRINCIPAL_INVESTIGATOR · University of Florida

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

female patients based on biological sex
18 to 85 years of age
diagnosis of primary, invasive, non-metastatic, stages I-III breast cancer
completed chemotherapy for breast cancer (anthracycline, alkylating agent and/or taxane) more than 6 months but less than 18 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation
absence of contraindications to exercise or to participate in study
study clinician approval
scheduled to receive surgery or radiation therapy during the intervention period
any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
lymphedema stage ≥2 prior to study enrollment
are pregnant
current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

What this trial measures

  • Change in brachial FMDBaseline, Following a 12-week intervention period, Following a 12-week observation period

    Flow-mediated dilation (FMD) is an established non-invasive measure of endothelial function. Brachial artery FMD will be determined via ultrasonography in response to reactive hyperemia following 5-min forearm ischemia.

  • Change in cardiac function (global longitudinal strain)Baseline, Following a 12-week intervention period, Following a 12-week observation period

    Global longitudinal strain is a marker of acute subclinical cardiotoxicity and is recommended for monitoring cancer patients at risk of cancer therapy-related cardiac dysfunction.

  • Percent completed vs. planned exercise frequencyThroughout the 12 weeks of supervised home-based exercise training

    The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise sessions/week.

  • Percent completed vs. planned exercise durationThroughout the 12 weeks of supervised home-based exercise training

    The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise min/session.

  • Percent completed vs. planned exercise intensityThroughout the 12 weeks of supervised home-based exercise training

    The investigators will collect information throughout the exercise intervention regarding % completed vs. planned exercise intensity/session.

  • Number of participants who experience adverse events as defined by most recent CTCAE throughout the exercise interventionThroughout the 12 weeks of supervised home-based exercise training

    To evaluate safety plans are in place for determination and monitoring of adverse events according to the most recent National Cancer Institute Common Terminology Criteria for Adverse Events. Classification for seriousness, expectedness, severity and relationship to study intervention will be based on the NIH provided definitions.